Get Permission Kumar and Jhunjhunwala: Epidemiology, clinical profile, management and outcome in patients of post covid mucormycosis at a tertiary care center in eastern UP


Introduction

COVID – 19 which is caused by coronavirus is a highly transmissible and pathogenic disease. It was first reported in Wuhan, China in 2019 and is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).1 It spreads faster than its related viral strains SARS-CoV and MERS-CoV and this rapid human to human transfer resulted in a worldwide pandemic.2 Covid-19 leads to decrease in the total number of lymphocytes which in turn inhibits body's cellular immune function,3, 4 which along with the complex interaction of different factors like preexisting comorbidities (diabetes mellitus, kidney disease), use of immunosuppressive drugs leads to secondary infection in patients. 5

India has seen a sudden rise in cases of a rare but notoriously fatal disease, rhino-orbital-cerebral mucormycosis during the second wave of covid-19 with contributing as high as 82% of the total global burden.6 First described by Paltauf, ROCM is caused by zygomycosis of order Mucorales 7 which is an angioinvasive nonseptate filamentous fungus generally found in soil, decaying organic matter. 8 It commonly affects orbit via invasion of paranasal sinuses or via direct inoculation and hematogenous spread. 8 Immunocompromised state, diabetes, solid organ transplantation, neutropenia, long-term systemic corticosteroid use, and iron overload are the associated risk factors.9, 10

Early diagnosis of mucormycosis which is based on clinical history and examination, imaging, microbiology and histopathology is important as medical and surgical treatment can reduce morbidity and mortality.11 MRI/CT findings are often nonspecific but are used to delineate the extent of disease. 12 Confirmation of diagnosis is done by KOH (fungal hyphae), culture and histopathology shows pathognomonic broad, irregular, non-septate, and right-angle branching hyphae along with evidence of angioinvasion and tissue infarction.12

In this study we aim to determine the patient demographics and population at risk, symptoms and signs, role of comorbidities and medication, treatment and outcome.

Materials and Methods

We performed a prospective study on patients admitted in post covid fungal ward as clinically and microbiologically proven case of mucormycosis with past history of COVID-19 infection. The demographic and clinical data were collected with the consent of the patients. The diagnosis of COVID-19 was based on RT-PCR test on nasopharyngeal/oropharyngeal swabs. Proven mucormycosis was defined as histopathologic, cytopathologic or direct microscopic examination showing fungal hyphae in biopsy specimen with associated tissue damage, or a positive culture result.6

Patients were admitted on the basis of clinical suspicion and a deep nasal swab and tissue from diagnostic nasal endoscopy was sent for KOH mount and fungal culture. Systemic antifungals were started on the basis of initial reports after consultation with ENT specialists. Magnetic resonance imaging (MRI) orbit, brain, and paranasal sinuses was performed for assessing the extent of disease. After getting the confirm culture report as mucormycosis all the patients underwent Retrobulbar injection Amphotericin B on 3 alternate days in dose 3.5 mg/ml. MRI was repeated after 1 week and based on clinical and radiological finding patients were divided into two groups, first group which showed regression of disease and second group where stable or progressive disease was seen. Second group then underwent endoscopic orbital debulking. All the patient also underwent endoscopic sinus debridement with biopsy and specimen was sent for histopathology, microbiology for culture and sensitivity test. Patients were then followed up for a period of 3 months to determine the outcome. Demographic and clinical characteristics were represented by frequencies and percentage. Fischer test was used to calculate P-value and significant p value was taken as <0.05.

Observation

The study group consisted of 43 patients with a mean age of 52.4 years. Maximum patients belonged to age group of 41-50 years (30.2%) with a gender ratio of 1.8:1. 28 (65.11%) patients were male while 15 (34.88%) were female. 36 (83.7%) patients belonged to rural background while 37 (86.05%) patients presented with concurrent history of diabetes out of which 5 had more than 1 risk factor.

27 (62.79%) patients had history of Covid-19 which was RTPCR confirmed whereas 16 (37.2%) had Covid defining symptoms like fever, malaise, breathlessness and sore throat with chest X-ray suggestive of covid-19 but never got tested. While 20 (66.67%) patients suffered for a duration less than 8 days, 25 (58.15%) and 13 (30%) needed steroids and oxygen respectively. Out of 25 patients, 11 used oral steroids, 6 used IV steroid and 8 used both oral and injectable steroids with mean duration of steroid use for 9.1 days. None of the patients in our study used any immunomodulatory drugs during illness.

All the patients presented to us with nasal stuffiness, swelling and pain on one side of face and periorbital area, headache, proptosis and ptosis. 28 (65.11%) patient had chemosis and 26 (60.46%) had loss of vision at the time of presentation. MRI of all the patients was done which showed sinus disease with orbit involvement.

Routine blood investigation was done and 18 (41.86%) patients had RBS in range of 200-300mg/dl, 11 (25.58%) patients had RBS in the range of 300-400mg/dl, 11 (25.58%) patients had RBS >400mg/dl while only 3 (6.97%) patients had RBS below 200mg/dl. Similar trend was seen with HbA1c with only 2 (4.65%) patient showing HbA1c in pre-diabetic range of 5.7-6.4. Rest of the patients had HbA1c level above 6.4 where a staggering 20 patients showed HbA1c above 10.

Out of 28 patients where chemosis was present, 19 patients had HbA1c level more than 10 and 18 had history of use of steroids. Chemosis showed significant association in our study with HbA1c with significant p value of 0.000126. No significant association was found between chemosis and steroid use with p value of 0.26 and between chemosis and oxygen use with p value of 0.307.

Out of 26 patients where loss of vision was present, 19 patients had history of use of steroids and 12 had history of oxygen requirement. Loss of vision showed significant association in our study with steroid use and oxygen requirement with significant p value of 0.03 and 0.008 respectively. No significant association was found between loss of vision and HbA1c with p value of 0.66.

On MRI, maximum 29 patient showed unilateral diffuse Para nasal sinus involvement whereas only 6 showed unilateral maxillary and ethmoid involvement and 8 showed bilateral involvement. Similarly, 2 patient showed involvement of medial orbit i.e. stage 3a whereas, only 1 patient had stage 3d i.e. bilateral orbit involvement. Out of 39 patients who had diffuse unilateral orbit involvement 13 were in stage 3b and 26 in stage 3c.

All the patients underwent Retrobulbar amphotericin B injection and MRI was done after 1 week, all the 3 patients in stage 3a showed regression. Out of 9 patients in stage 3b, 7 showed regression whereas 6 patients who showed stable/progressive disease then underwent orbital debulking and showed regression. Similarly, all the patient in stage 3c underwent orbital debulking where 12 showed regression of disease, 11 showed stable and 3 showed progressive course. 1 patient in stage 3d showed regression to stage 3c with retrobulbar and intralesional amphotericin B injection and a further stable course after orbital debulking.

Table 1

Clinical-demographic profile

S.No.

H/O DM

HbA1C

Covid +Ve

Steroid

O2

Age

Sex

RBS

R/U

Proptosis

Ptosis

Chemosis

Loss of vision

1

No

13.2

Yes

Yes

No

74

M

214.5

R

Yes

Yes

Yes

No

2

Yes

13.7

Yes

Yes

No

45

F

354.7

R

Yes

Yes

Yes

Yes

3

Yes

8.7

Yes

No

Yes

80

M

362.6

R

Yes

Yes

No

Yes

4

Yes

8.6

Yes

No

Yes

50

F

277

R

Yes

Yes

No

Yes

5

Yes

10.2

No

Yes

No

56

M

302.2

R

Yes

Yes

Yes

No

6

Yes

11.6

No

Yes

No

60

F

555

R

Yes

Yes

Yes

No

7

Yes

10.2

Yes

Yes

No

62

M

213

R

Yes

Yes

Yes

Yes

8

No

7

Yes

Yes

YES

45

M

436

R

Yes

Yes

No

Yes

9

Yes

13.2

No

No

No

40

M

190.7

R

Yes

Yes

Yes

No

10

Yes

11.8

Yes

No

No

34

F

223

R

Yes

Yes

Yes

Yes

11

Yes

8.8

Yes

Yes

Yes

56

F

304.2

R

Yes

Yes

No

Yes

12

Yes

12.6

Yes

Yes

No

60

M

242.9

R

Yes

Yes

Yes

Yes

13

Yes

12.2

Yes

No

No

55

M

444

R

Yes

Yes

Yes

Yes

14

Yes

8.8

No

No

No

51

M

254.4

R

Yes

Yes

No

No

15

NO

10.2

Yes

No

No

45

M

338.4

R

Yes

Yes

Yes

Yes

16

Yes

11.1

Yes

Yes

No

36

F

238.5

R

Yes

Yes

Yes

Yes

17

Yes

10.2

No

No

No

48

M

275

R

Yes

Yes

Yes

No

18

Yes

10.8

Yes

Yes

No

48

M

333.3

U

Yes

Yes

Yes

Yes

19

Yes

8.1

Yes

Yes

Yes

45

M

198.9

R

Yes

Yes

Yes

Yes

20

Yes

8.6

No

No

No

40

F

224.4

R

Yes

Yes

No

No

21

No

6.1

No

No

No

60

F

336.7

R

Yes

Yes

No

No

22

Yes

7.8

Yes

Yes

Yes

72

M

221.1

U

Yes

Yes

No

Yes

23

Yes

7.1

No

No

No

43

M

456

R

Yes

Yes

No

No

24

Yes

8.9

Yes

Yes

No

66

M

246

U

Yes

Yes

Yes

Yes

25

Yes

13

No

No

No

74

M

450

R

Yes

Yes

Yes

No

26

Yes

14.6

Yes

Yes

YES

69

M

380.9

R

Yes

Yes

Yes

Yes

27

Yes

8.2

Yes

Yes

No

35

F

224

R

Yes

Yes

No

Yes

28

Yes

12.4

Yes

Yes

Yes

40

M

178.7

R

Yes

Yes

Yes

Yes

29

Yes

8.8

Yes

Yes

Yes

40

M

461.8

R

Yes

Yes

Yes

Yes

30

Yes

12.8

Yes

Yes

No

55

F

224

R

Yes

Yes

Yes

Yes

31

Yes

7.9

Yes

Yes

No

42

M

314

U

Yes

Yes

No

No

32

Yes

8.9

No

Yes

No

50

M

444

R

Yes

Yes

No

Yes

33

Yes

12.6

No

No

No

39

f

254.9

U

Yes

Yes

Yes

No

34

No

5.8

No

No

No

40

F

202

R

Yes

Yes

Yes

No

35

Yes

14.4

Yes

Yes

Yes

45

M

502.7

R

Yes

Yes

Yes

No

36

Yes

6.4

No

No

No

50

M

371

R

Yes

Yes

No

Yes

37

Yes

8.9

Yes

Yes

No

66

M

222

U

Yes

Yes

Yes

No

38

Yes

6.7

No

No

No

70

M

524

R

Yes

Yes

No

Yes

39

Yes

7.7

Yes

Yes

Yes

50

M

377

R

Yes

Yes

Yes

Yes

40

Yes

9.8

Yes

Yes

Yes

55

F

226

R

Yes

Yes

Yes

Yes

41

Yes

11.3

Yes

Yes

Yes

36

F

666

R

Yes

Yes

No

Yes

42

No

6.6

No

No

No

62

M

276

R

Yes

Yes

Yes

No

43

Yes

8.9

No

No

No

65

F

495

R

Yes

Yes

Yes

Yes

Discussion

The COVID-19 pandemic started in wuhan, China back in December 2019. 13 A novel coronavirus was identified by the Chinese Center for Disease Control and Prevention (CDC) on 7 January 2020. Coronavirus consumes immune cells (CD4+, CD8+ and Lymphocytes) leading to decrease in the total number of lymphocytes which in turn inhibits body's cellular immune function, 13 which along with the complex interaction of different factors like preexisting comorbidities (diabetes mellitus, kidney disease), use of immunosuppressive drugs, hospital acquired infection leads to secondary infection in patients. 14

The mucorals are angioinvasive, they have affinity for arteries and grow along the internal elastic lamina, causing thrombosis and necrosis of host tissue. 15 Progression of the disease is either direct through the thin lamina papyracea of the ethmoid bone, infratemporal fossa, inferior orbital fissure, or orbital apex or leads to the vascular occlusion of the orbital contents. 15 Intracranial involvement occurs also from the invasion by the way of the superior orbital fissure, ophthalmic vessels and cribriform plate, through the carotid artery, or possibly via a perineural route. 16

The use of immunosuppressant drugs and immunomodulators in COVID also increases the risk of secondary infection. Currently the use of intravenous methylprednisolone 0.5-1 mg/kg/day for three days in moderate cases and 1-2 mg/kg/day in severe cases is recommended by Government of India (GOI) 17 and use of dexamethasone (6 mg per day for a maximum of 10 days) in patients on supplemental oxygen is recommended by The National Institute of Health. 18

Mucormycosis is likely to develop during the middle and later stages of COVID-19. 19 Most common association was found between diabetes mellitus and mucormycosis in India. In a large meta-analysis on 851 cases presence of DM was found to be an independent risk factor (Odds ratio [OR] 2.69; 95% Confidence Interval 1.77–3.54; P < 0.001) and the most common species isolated was Rhizopus (48%). 20 Voriconazole use was also found to be a predisposing factor in mucormycosis in the same study. While long term use of corticosteroids has often been associated with several opportunistic fungal infection, even a short course of corticosteroids has been reported to link with mucormycosis especially in people with DM. 21 In a retrospective observational study on 2826 patients from all over India by Sen, Mrittika et al 6 in july 2021, they found that maximum cases were reported from Gujarat (22%) and Maharashtra (21%) with a male predilection and a mean age of 51.9 years. Majority of patients were diagnosed when presented in stage 3 (involvement of orbit). They concluded that DM and use of corticosteroids are important and independent risk factor for mucormycosis along with covid which in itself is an immunocompromised state. In a systemic review of cases of mucormycosis from all over world and india, Singh AK et al 22 concluded that increase in cases in india during covid second wave is due to the trinity of diabetes who have high prevalence genetically, rampant use of corticosteroid which increases blood glucose and opportunistic fungal infection and COVID-19 the disease itself which leads to cytokine storm, lymphopenia, endothelial damage. In a similar study done by Gupta SK 23 in 2017, mean age was found to be 50 years with male preponderance. He concluded that uncontrolled diabetes is the biggest risk factor for rhino orbital mucormycosis.

The mean age of our study is 52.4 years with male predominance similar to the study done by Sen, Mrittika et al. Most of the patient in our study were rural area where the lack of proper care and rampant use of steroids is prevalent. 5 patients had more than 1 risk factor, out of which 1 patient had history of long term steroid use which in itself is a risk factor for mucormycosis. All the patient presented in stage 3 after the involvement of orbit. Diabetes mellitus was the most common underlying predisposing factor in our study and steroid use the second most common with as many as 25 patients who needed steroids during their covid illness similar findings were also observed by Sen, Mrittika et al 15 and singh AK et al. 22 The mean duration of steroid use was 9.1 days (short duration). Use of oxygen was found only in 13 patients.

All the patients presented to us in stage 3 disease with nasal stuffiness, swelling and pain on one side of face and periorbital area, headache, proptosis and ptosis. MRI of all the patients showed sinus disease with orbit involvement. Most patients in our study had uncontrolled diabetes with only 3 patients having RBS below 200mg/dl at the time of presentation and only 2 patient having HbA1c below 6.4 whereas a staggering 20 patients had HbA1c above 10.

Use of steroid and oxygen increases with the increase in severity of covid-19 illness along with the use of broad spectrum antibiotics and antifungal in hospital setup. With increasing severity of covid-19 and use of steroid long with uncontrolled diabetes, severity of symptoms for mucormycosis also increases and hence the grave consequences. All the 43 patients were alive at 3 month follow –up.

Conclusion

Patients with rhino orbital mucormycosis can be managed with orbital debulking with perilesional, intralesional and Retrobulbar amphotericin B with IV amphotericin B and functional endoscopic sinus surgery to avoid distressing surgery like exenteration.

Acknowledgment

None.

Source of Funding

None.

Conflict of Interest

None.

References

1 

M A Shereen S Khan A Kazmi N Bashir R Siddique COVID-19 infection: Origin, transmission, and characteristics of human coronavirusesJ Adv Res20202491810.1016/j.jare.2020.03.005

2 

T Singhal A Review of Coronavirus Disease-2019 (COVID-19)Indian J Pediatr2020874281610.1007/s12098-020-03263-6

3 

N Chen M Zhou X Dong Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive studyLancet2020395102235071310.1016/S0140-6736(20)30211-7

4 

RP Maurya Ocular trauma during COVID-19 crisis: Trends and managementInd J Clin Exp Ophthalmol2020644789

5 

S Mehta A Pandey Rhino-Orbital Mucormycosis Associated With COVID-19Cureus2020129e1072610.7759/cureus.10726PMCID

6 

M Sen SG Honavar R Bansal S Sengupta R Rao U Kim Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India - Collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC), Report 1Indian J Ophthalmol202169716729010.4103/ijo.IJO_1565_21PMCID

7 

A Paltauf Mycosis mucorinaVirchows Arch Pathol Anat Physiol Klin Med188510254364

8 

J Kirszrot PAD Rubin Invasive fungal infections of the orbitInt Ophthalmol Clin20074721173210.1097/IIO.0b013e31803776db

10 

RP Maurya Indications for orbital exenteration in COVID-19 associated Rhino-orbit-cerebral MucormycosisIP Int J Ocul Oncol Oculoplast2021721058

11 

SS Awal SS Biswas SK Awal Rhino-orbital mucormycosis in COVID-19 patients-a new threatEgypt J Radiol Nucl Med202152115210.1186/s43055-021-00535-9

13 

N Chen M Zhou X Dong Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive studyLancet2020395102235071310.1016/S0140-6736(20)30211-7

14 

S Mehta A Pandey Rhino-Orbital Mucormycosis Associated With COVID-19Cureus2020129e1072610.7759/cureus.10726

15 

M Sen S Lahane P Tatyarao R Parekh S Honavar Mucor in a Viral LandIndian J Ophthalmol20216922445210.4103/ijo.IJO_3774_20

16 

RD Baker Mucormycosis; a new disease?J Am Med Assoc195716310805810.1001/jama.1957.02970450007003

17 

Clinical management protocol for COVID-19. [Jul; 2020]https://www.mohfw.gov.in/pdf/ClinicalManagementProtocolforCOVID19.pdf

18 

WS Lim JR Emberson M Mafham JL Bell L Linsell N Staplin Dexamethasone in Hospitalized Patients with Covid-19N Engl J Med2020384869370410.1056/NEJMoa2021436

19 

G Song G Liang W Liu Fungal Co-infections Associated with Global COVID-19 Pandemic: A Clinical and Diagnostic Perspective from ChinaMycopathologia2020185459960610.1007/s11046-020-00462-9

20 

W Jeong C Keighley R Wolfe The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reportsClin Microbiol Infect2019251263410.1016/j.cmi.2018.07.011

21 

MS Lionakis DP Kontoyiannis Glucocorticoids and invasive fungal infectionsLancet2003362939818283810.1016/S0140-6736(03)14904-5

22 

A K Singh R Singh S R Joshi A Misra Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in IndiaDiabetes Metab Syndr202115410214610.1016/j.dsx.2021.05.019

23 

SK Gupta Clinical Profile of Mucormycosis: A Descriptive analysesInt J Sci Stud2017561603



jats-html.xsl


This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

  • Article highlights
  • Article tables
  • Article images

Article History

Received : 09-05-2022

Accepted : 02-06-2022


View Article

PDF File   Full Text Article


Copyright permission

Get article permission for commercial use

Downlaod

PDF File   XML File   ePub File


Digital Object Identifier (DOI)

Article DOI

https://doi.org/ 10.18231/j.ijooo.2022.026


Article Metrics






Article Access statistics

Viewed: 886

PDF Downloaded: 559